Oragenics Inc (NYSEAMERICAN:OGEN) was down 6.5% on Monday . The stock traded as low as $0.85 and last traded at $0.87. Approximately 949,917 shares traded hands during mid-day trading, a decline of 62% from the average daily volume of 2,482,232 shares. The stock had previously closed at $0.93.

Oragenics (NYSEAMERICAN:OGEN) last posted its quarterly earnings data on Tuesday, November 13th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.13).

In other Oragenics news, major shareholder Family Lp Koski purchased 100,000 shares of the business’s stock in a transaction on Monday, September 17th. The stock was bought at an average cost of $0.42 per share, with a total value of $42,000.00. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.

ILLEGAL ACTIVITY WARNING: This news story was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.dailypolitical.com/2018/11/20/oragenics-ogen-shares-down-6-5.html.


Oragenics, Inc focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients.

Recommended Story: What are the benefits of buying treasury bonds?

Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.